Abstract
ObjectiveTo systematically evaluate the efficacy and safety of olaparib in the treatment of recurrent platinum-sensitive ovarian cancer.MethodsThe Cochrane Library, PubMed, Chinese Biomedical Literature Database, CNKI, VIP Database, Wanfang Science and Technology Database were searched for randomized controlled trials (RCTs) of olaparib in the treatment of recurrent platinum-sensitive ovarian cancer from the establishment of each database to January 2022. Two reviewers independently evaluated the quality of the literature, extracted the data, and cross-checked the methodological quality. Meta-analysis was performed using RevMan 5.4 software.ResultsA total of 7 RCTs were included, including 2406 patients, There were 1497 patients in treatment groups and 909 patients in the control group. Meta-analysis results showed that in terms of effectiveness, the overall survival time of patients in the olaparib group [HR=1.24, 95%CI(1.06, 1.45), P=0.006]; in terms of safety, for all grades of adverse events (including nausea, fatigue, vomiting, diarrhea, abdominal pain, and headache), [HR=1.54, 95%CI(1.38, 1.71), P=0.0002], for grade 3 or higher adverse events (including nausea, fatigue, vomiting, diarrhea, abdominal pain, and headache), [HR=2.13, 95%CI(1.61, 2.81), P=0.003], there were significant differences compared with the control group, suggesting that the risk of adverse reactions in the experimental group was higher than that in the control group. Subgroup analysis showed that only abdominal pain, headache and vomiting were not statistically significant, and other adverse reactions were statistically significant.ConclusionBased on the existing clinical evidence, olaparib in the treatment of recurrent platinum-sensitive ovarian cancer has a longer overall survival than the control group. It is an ideal regimen, but the incidence of adverse reactions is high.
Highlights
In order to further systematically evaluate the efficacy and safety of Olaparib in the treatment of ovarian cancer, the following inclusion criteria were used: [1] Included population: the diagnosis and inclusion criteria were consistent with the diagnostic criteria of recurrent platinum sensitive ovarian cancer, regardless of gender and race; [2] Literature type: prospective or retrospective studies; [3] Interventions: Experimental group: olaparib alone and combined with conventional chemotherapy; Control group: conventional chemotherapy or placebo
A total of 63 relevant literatures were obtained through database retrieval, and 8 were obtained through other methods, all of which were in English. 16 duplicate literatures were excluded, 9 inconsistent literatures were excluded from reading titles and abstracts, and 25 literatures were excluded from reading full text
Any Grade of Adverse Reactions Caused by Olaparib Six studies compared any grade of adverse reactions, including nausea, fatigue, vomiting, diarrhea, abdominal pain, and headache, and meta-analysis of the results showed that the relative risk of any grade of adverse reactions was higher in the olaparib group than in the control group [RR=1.54, 95%CI (1.38, 1.71), P=0.0002], and had statistical significance (P < 0.05)
Summary
The Cochrane Library, PubMed, Chinese Biomedical Literature Database, CNKI, VIP Database, Wanfang Science and Technology Database were searched for randomized controlled trials (RCTs) of olaparib in the treatment of recurrent platinumsensitive ovarian cancer from the establishment of each database to January 2022.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
